- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.05. | Parkinson's drug from Biogen, Denali comes up short | ||
| 21.05. | RA Capital banks $75M for a biotech SPAC | ||
| 21.05. | Lilly's triple-acting obesity drug hits goal in Phase 3 trial | ||
| 21.05. | BioMarin notches win in study that could expand use of top-selling medicine | ||
| 21.05. | In Alzheimer's, Bristol Myers sees big promise beyond amyloid | ||
| 20.05. | After raising $800M, Parabilis seeks an IPO to pursue 'undruggable' targets | ||
| 20.05. | Bristol Myers deepens AI investment with Anthropic deal | ||
| 20.05. | Oorja, run by Acceleron veterans, launches to make new fibrosis drugs | ||
| 20.05. | Immunovant's potential autoimmune 'blockbuster'; Wave's RNA editing update | ||
| 19.05. | BioMarin drug acquired in buyout misses goal in rare disease study | ||
| 19.05. | A migraine drugmaker heads to the public markets through reverse merger | ||
| 19.05. | Relay drug shows early promise against rare blood vessel diseases | ||
| 18.05. | FDA approves AstraZeneca's new kind of hypertension drug | ||
| 18.05. | Merck ADC, licensed from China, hits mark in first big global trial | ||
| 18.05. | Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug | ||
| 18.05. | Regeneron immunotherapy combo comes up short in melanoma trial | ||
| 18.05. | Unlocking more value from mature drug products through strategic outsourcing | ||
| 15.05. | FDA hold puts Aardvark Prader-Willi drug in limbo | ||
| 15.05. | Supreme Court preserves access to abortion pill by mail | ||
| 15.05. | Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers | ||
| 15.05. | India's pharma industry is going global. But can it catch up to China? | ||
| 14.05. | Create Medicines raises $122M to bolster in vivo CAR-T therapies | ||
| 14.05. | Biogen pushing tau drug forward despite Alzheimer's study failure | ||
| 14.05. | With new data, Regenxbio to seek FDA approval of Duchenne gene therapy | ||
| 13.05. | FDA's leadership void leaves biotech with renewed 'uncertainty' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.